Initial treatment of transplant-eligible patients in multiple myeloma.
about
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.The comprehensive clinical management of multiple myeloma and related-plasma cell disorders.Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China.
P2860
Initial treatment of transplant-eligible patients in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Initial treatment of transplant-eligible patients in multiple myeloma.
@en
type
label
Initial treatment of transplant-eligible patients in multiple myeloma.
@en
prefLabel
Initial treatment of transplant-eligible patients in multiple myeloma.
@en
P2093
P2860
P1476
Initial treatment of transplant-eligible patients in multiple myeloma.
@en
P2093
Laura Rosiñol
Phillipe Moreau
Shaji Kumar
P2860
P356
10.1586/17474086.2014.871200
P50
P577
2014-01-07T00:00:00Z